Pharmacology & Therapeutics

Article	Citations
Editorial Board	326
Potential neonatal toxicity of new psychoactive substances	321
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	282
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	259
Endothelial dysfunction as a complication of anti-cancer therapy	239
Inflammation, lipids, and pain in vulvar disease	219
Adenosine receptor signalling as a driver of pulmonary fibrosis	214
Non-canonical G protein signaling	185
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	184
In cancer, all roads lead to NADPH	183
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	173
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	164
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	162
Matrikines in the skin: Origin, effects, and therapeutic potential	139
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	137
Collateral lethality: A unique type of synthetic lethality in cancers	136
Unfolded protein responses: Dynamic machinery in wound healing	135
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	131
The role of macrophages in asthma-related fibrosis and remodelling	125
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	125
Management of drug-resistant hypertension as a heterogeneous disorder	123
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	117
Cell-based therapies for vascular regeneration: Past, present and future	110
TLR4 biased small molecule modulators	106
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	105

Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	103
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	98
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	98
Boron in cancer therapeutics: An overview	97
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	97
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	95
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	91
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	91
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	90
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	89
Contribution of non-selective membrane channels and receptors in epilepsy	88
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	86
Dysregulation of metabolic pathways in pulmonary fibrosis	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	86
TAAR1 as an emerging target for the treatment of psychiatric disorders	86
Editorial Board	84
Wnt signaling: A prospective therapeutic target for chronic pain	84
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	83
Review: Sex-related differences in the treatment of cardiac arrhythmia	83
Bispecific antibodies for the treatment of neuroblastoma	79
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	77
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	75
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	74
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	73
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	72
PGRMC1: An enigmatic heme-binding protein	72
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	72
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	71
Natural products that alleviate depression: The putative role of autophagy	71
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	70
Pharmacological treatment of cardiogenic shock – A state of the art review	70
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	68
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	67
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	66
DNA methylation in cell plasticity and malignant transformation in liver diseases	66
Stabilizing the neural barrier – A novel approach in pain therapy	63
Advances in pathogenesis and therapeutic strategies for osteoporosis	63
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	62
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	61
Optimizing drug therapies in cardiac amyloidosis	61
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	60
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	60
Therapeutic targeting of DNA methylation alterations in cancer	60
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	59
Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications	58
Drug repurposing for COVID-19: Approaches, challenges and promising candidates	58
Recent advances in riboflavin transporter RFVT and its genetic disease	58
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics	57

The role of drug-metabolizing enzymes in synthetic lethality of cancer	56
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	56
Regulation of feeding and therapeutic application of bioactive peptides	56
In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress	56
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	55
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	55
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	55
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	54
Organic anion transporters in remote sensing and organ crosstalk	52
Consideration of albumin-mediated hepatic uptake for highly protein-bound anionic drugs: Bridging the gap of hepatic uptake clearance between in vitro and in vivo	51
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	50
Editorial Board	50
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	50
Editorial Board	50
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	50
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	50
MicroRNAs in drug addiction: Current status and future perspectives	50
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications	49
CDNF and ER stress: Pharmacology and therapeutic possibilities	49
Pharmacological potential of cyclic nucleotide signaling in immunity	48
Emerging methods for and novel insights gained by absolute quantification of mitochondrial DNA copy number and its clinical applications	48
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	48
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	47
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	47
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	47
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	47
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	47
Editorial Board	46
Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders	46
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	46
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	46
Modulation of hyaluronan signaling as a therapeutic target in human disease	46
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	45
The role and participation of immune cells in the endometrial tumor microenvironment	45
Resolving inflammation by TAM receptor activation	45
Exploring the landscape of post-translational modification in drug discovery	45
Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination	44
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	44
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	44
Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?	44
G protein-coupled estrogen receptor biased signaling in health and disease	44
Molecular mechanisms of ferroptosis and their involvement in brain diseases	44
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	44
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	43
Understanding the molecular bridges between the drugs and immune cell	43
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	42
Potential targeting of the tumor microenvironment to improve cancer virotherapy	41
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	41
Platelet lipid metabolism in vascular thrombo-inflammation	40
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	40
Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology	40
Editorial Board	39
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	39
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	39
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	39
Plant-derived nanovesicles and therapeutic application	39
The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases	39
Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy	38
Early life adversities, psychopathologies and novel pharmacological strategies	38
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	38
From bench to clinic: Emerging therapies for corneal scarring	37
Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities	37
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	37
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them	37
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	37
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	36
Editorial Board	36
Resolution of inflammation: An organizing principle in biology and medicine	36
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	36
Prolactin and pain of endometriosis	35
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	35
Editorial Board	35
The antidepressant actions of ketamine and its enantiomers	35
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	34
Retina-directed gene therapy: Achievements and remaining challenges	34
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	33
Multitasking bamboo leaf-derived compounds in prevention of infectious, inflammatory, atherosclerotic, metabolic, and neuropsychiatric diseases	33
Treatment of overdose in the synthetic opioid era	33
Anti-cancer activity of sustained release capsaicin formulations	33
Biased signaling in drug discovery and precision medicine	33

Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	33
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	32
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	32
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	32
Bile acids and neurological disease	32
Spotlight on plasticity-related genes: Current insights in health and disease	31
Editorial Board	31
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	31
The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy	31
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics	31
Gene and stem cell therapy for inherited cardiac arrhythmias	31
Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte?	31
Gut dysbiosis, defective autophagy and altered immune responses in neurodegenerative diseases: Tales of a vicious cycle	31
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities	31
Lessons learned from 20 years of preclinical testing in pediatric cancers	31